18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer

Official record

Identifier

NCT03181867

Recruiting locations

country

United States

Interventions studied

18F-DCFPyL18F-FDGPSMA-11

Lead sponsor

National Cancer Institute (NCI)

Target enrolment

360 participants

Study type

INTERVENTIONAL

Phase

Phase 2

Status

Active, not recruiting

First posted

Jun 9, 2017

Last updated on the registry

Sep 2, 2026

Age

18 Years

Sex

MALE

Study contact

No public contact is listed on the official record.

Eligibility criteria

Reproduced verbatim from the official record. Eligibility is decided by the study team, never by this page.

* INCLUSION CRITERIA:
* Age greater than or equal to 18 years old.
* Eastern Cooperative Oncology Group (ECOG) Performance score of 0 to 2.
* Ability of subject to understand and the willingness to sign a written informed consent document.
* Histologically confirmed adenocarcinoma of the prostate.
* Patients (including those receiving androgen deprivation therapy) fit criteria for one of the following categories:

  * Cohort 1 known localized high risk prostate cancer (PSA \>10, Gleason 8-10 or clinical stage \>T2c) with evidence of disease on standard imaging, OR
  * Cohort 2 nonspecific or no evidence of disease on standard imaging modality AND biochemical prostate cancer relapse with a PSA greater than or equal to 0.2 ng/mL. Patients must be willing to undergo mandatory research biopsy
* Participants must be co-enrolled on a MIB, UOB, GMB or ROB protocol.
* The effects of 18F-DCFPyL on the developing human fetus are unknown. For this reason, individuals must agree to use adequate contraception with their partner (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation and 2 months after 18F-DCFPyL scan. Should a partner become pregnant or suspect she is pregnant while her partner is participating in this study, she should inform the treating physician immediately.

EXCLUSION CRITERIA:

* Subjects for whom participating would significantly delay the scheduled standard of care therapy.
* Subjects with any coexisting medical or psychiatric condition that is likely to interfere with study procedures and/or results.
* Subjects with severe claustrophobia unresponsive to oral anxiolytics
* Other medical conditions deemed by the principal investigator (or associates) to make the subject unsafe/ineligible for protocol procedures.
* Subjects weighing greater than 350 lbs. (weight limit for scanner table), or unable to fit within the imaging gantry.
* Serum creatinine greater than 2 times the upper limit of normal.

Indexed under

Prostate Cancer